Trial Profile

A Phase 1/2 Study of agenT-797 to Treat Moderate to Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2 or Influenza

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 17 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AGENT-797 (Primary)
Indications SARS-CoV-2 acute respiratory disease
Focus Adverse reactions; First in man
Sponsors MiNK Therapeutics

Most Recent Events

14 May 2024 According to a MiNK Therapeutics media release, the company announced presentation at the upcoming ATS Annual Meeting on May 21, 2024, will highlight the clinical efficacy of agenT-797
06 Feb 2024 Results published in a MiNK Therapeutics media release.
06 Feb 2024 According to a MiNK Therapeutics media release, today announced publication of results in Nature Communications from this phase 1/2 study of agenT-797 in patients with moderate-to-severe acute respiratory distress secondary to SARS-CoV-2.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com